Sensuke Konno
Research Subjects
Research Interests
Sensuke Konno has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
Muhammad Choudhury
Professor and Chairman, Department of Urology, New York Medical College, Valhalla 10595, USA
20 shared publicationsMajid Eshghi
New York Medical College
12 shared publicationsBobby Alexander
Valhalla, NY
5 shared publicationsJohn Phillips
Valhalla, NY
4 shared publicationsJonathan Bloom
Department of Urology, New York Medical College, Valhalla, NY, 10595, USA
4 shared publicationsAndrew Fishman
Valhalla, NY
3 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by Elmer Press, Inc. in World Journal of Nephrology and Urology
- Vol. 15 (3) , 82-89
Possible Mitigation of Renal Ischemia-Reperfusion Injury With Monk Fruit ( Siraitia grosvenori ) Extract in a Rat Model
Background: Renal ischemia, induced during various kidney surgeries, alarmingly leads to renal inflammation and injuries. We hypothesized that oxidative stress (OXS) could be a primary cause of renal ischemia-reperfusion injury (RIRI), and that antioxidants may mitigate it. Hence, we investigated if monk fruit extract, LLE, with antioxidant activity might reduce the incidence of warm ischemia-induced RIRI in rats. Methods: Sprague–Dawley rats were randomly assigned to three groups: (1) Sham, (2) ischemia-reperfusion (RIR), and (3) RIR with LLE supplementation (RIR + LLE). The rat kidney was surgically exposed and subjected to 40-min ischemia by renal pedicle clamping, followed by 24-h reperfusion. LLE (150 μg) was given to rats 30 min prior to ischemia and soon after reperfusion began for 24 h. Results: The RIR group showed significantly elevated blood urea nitrogen (BUN) and creatinine (Cr) levels, indicating renal dysfunction, and palpable kidney injuries/alterations were also detected by histopathologic examination. However, the kidneys in the RIR + LLE group appeared merely normal with significantly reduced BUN/Cr levels. Additionally, the OXS level was ∼2.3-fold greater, two antioxidant enzymes (catalase and glutathione peroxidase) were inactivated, and specific kidney injury markers (neutrophil-gelatinase-associated lipocalin, kidney injury molecule 1, and clusterin) were up-regulated in the RIR group. In contrast, a few changes in OXS, enzymatic activities, and marker expression were observed in the RIR + LLE group. Conclusion: This study demonstrates that OXS plays a primary role in RIRI, while LLE with antioxidant activity protects the kidneys from it. Thus, LLE warrants consideration as a potential perioperative renoprotective agent for clinical use.
- 1 July 2026
- Published by Elmer Press, Inc. in World Journal of Nephrology and Urology
- Vol. 15 (3) , 82-89
Open AccessPossible Mitigation of Renal Ischemia-Reperfusion Injury With Monk Fruit ( Siraitia grosvenori ) Extract in a Rat Model
Background: Renal ischemia, induced during various kidney surgeries, alarmingly leads to renal inflammation and injuries. We hypothesized that oxidative stress (OXS) could be a primary cause of renal ischemia-reperfusion injury (RIRI), and that antioxidants may mitigate it. Hence, we investigated if monk fruit extract, LLE, with antioxidant activity might reduce the incidence of warm ischemia-induced RIRI in rats. Methods: Sprague–Dawley rats were randomly assigned to three groups: (1) Sham, (2) ischemia-reperfusion (RIR), and (3) RIR with LLE supplementation (RIR + LLE). The rat kidney was surgically exposed and subjected to 40-min ischemia by renal pedicle clamping, followed by 24-h reperfusion. LLE (150 μg) was given to rats 30 min prior to ischemia and soon after reperfusion began for 24 h. Results: The RIR group showed significantly elevated blood urea nitrogen (BUN) and creatinine (Cr) levels, indicating renal dysfunction, and palpable kidney injuries/alterations were also detected by histopathologic examination. However, the kidneys in the RIR + LLE group appeared merely normal with significantly reduced BUN/Cr levels. Additionally, the OXS level was ∼2.3-fold greater, two antioxidant enzymes (catalase and glutathione peroxidase) were inactivated, and specific kidney injury markers (neutrophil-gelatinase-associated lipocalin, kidney injury molecule 1, and clusterin) were up-regulated in the RIR group. In contrast, a few changes in OXS, enzymatic activities, and marker expression were observed in the RIR + LLE group. Conclusion: This study demonstrates that OXS plays a primary role in RIRI, while LLE with antioxidant activity protects the kidneys from it. Thus, LLE warrants consideration as a potential perioperative renoprotective agent for clinical use.
- Open Access
- 15 December 2020
- Published by Baishideng Publishing Group Inc. in World Journal of Diabetes
- Vol. 11 (12) , 572-583
SX-fraction: Promise for novel treatment of type 2 diabetes
SX-fraction (SXF) is a bioactive glycoprotein with anti-diabetic and hypoglycemic activities that have been documented in several reports. We have reviewed those studies herein and also explored the possible mechanism of its hypoglycemic activity. The early animal studies of SXF using diabetic mice showed the significant reduction in the three diabetic parameters, serum glucose, insulin, and triglyceride, suggesting its anti-diabetic activity. The limited clinical studies also showed that SXF led to the significant reduction in the fasting blood glucose levels of type 2 diabetic patients within 2 wk or a month, suggesting its hypoglycemic activity. To explore the hypoglycemic mechanism of SXF, its possible effects on the insulin signal transduction pathway was examined in vitro. Particularly, activities of insulin receptor, insulin receptor substrate 1, and protein kinase B, which are essential elements playing a key regulatory role in the signal pathway, were studied using skeletal muscle L6 cells. The status of these three parameters were examined under a high glucose (35 mmol/L) milieu with SXF and assessed using the enzyme-linked immunosorbent assay. Such studies revealed that all three parameters (insulin receptor, insulin receptor substrate 1, and protein kinase B) were inactivated by high glucose, indicating a disruption of the signal pathway. However, such an inactivation was reversed or re-activated by SXF to successfully carry out the sequential signaling events. In fact, a measurement of glucose uptake in cells showed that SXF did increase a glucose uptake while high glucose decreased it. Therefore, SXF has anti-diabetic and hypoglycemic activities through activation of the insulin signal pathway and appears to be a safe, natural agent for lowering the serum glucose levels in type 2 diabetic patents and improving their diabetic conditions.
- 15 December 2020
- Published by Baishideng Publishing Group Inc. in World Journal of Diabetes
- Vol. 11 (12) , 572-583
Open AccessSX-fraction: Promise for novel treatment of type 2 diabetes
SX-fraction (SXF) is a bioactive glycoprotein with anti-diabetic and hypoglycemic activities that have been documented in several reports. We have reviewed those studies herein and also explored the possible mechanism of its hypoglycemic activity. The early animal studies of SXF using diabetic mice showed the significant reduction in the three diabetic parameters, serum glucose, insulin, and triglyceride, suggesting its anti-diabetic activity. The limited clinical studies also showed that SXF led to the significant reduction in the fasting blood glucose levels of type 2 diabetic patients within 2 wk or a month, suggesting its hypoglycemic activity. To explore the hypoglycemic mechanism of SXF, its possible effects on the insulin signal transduction pathway was examined in vitro. Particularly, activities of insulin receptor, insulin receptor substrate 1, and protein kinase B, which are essential elements playing a key regulatory role in the signal pathway, were studied using skeletal muscle L6 cells. The status of these three parameters were examined under a high glucose (35 mmol/L) milieu with SXF and assessed using the enzyme-linked immunosorbent assay. Such studies revealed that all three parameters (insulin receptor, insulin receptor substrate 1, and protein kinase B) were inactivated by high glucose, indicating a disruption of the signal pathway. However, such an inactivation was reversed or re-activated by SXF to successfully carry out the sequential signaling events. In fact, a measurement of glucose uptake in cells showed that SXF did increase a glucose uptake while high glucose decreased it. Therefore, SXF has anti-diabetic and hypoglycemic activities through activation of the insulin signal pathway and appears to be a safe, natural agent for lowering the serum glucose levels in type 2 diabetic patents and improving their diabetic conditions.
- 26 August 2020
- Published by Medip Academy in International Journal of Research in Medical Sciences
- Vol. 8 (9) , 3154
Chemosensitizing effect of maitake mushroom extract on carmustine cytotoxicity in human bladder cancer cells
Background: Despite several therapeutic options available for bladder cancer, the outcomes are less satisfactory. To find a more effective modality, we were interested in the bioactive mushroom extract, PDF, which has been shown to sensitize certain anticancer drugs. Accordingly, we investigated if cytotoxic effects of several anticancer drugs used on bladder cancer patients could be enhanced with PDF in vitro.Methods: Human bladder cancer T24 cells were treated with four anticancer drugs, carmustine (BCNU), 5-fluorouracil (5FU), cisplatin (CPL), and doxorubicin (DOX) alone, their combinations, or in combination with PDF, and cell viability was determined. To explore the anticancer mechanism, the status of glyoxalase I (Gly-I), an enzyme involved in the drug resistance of cancer cells, and oxidative stress that can cause severe cellular injury/damage was also assessed.Results: BCNU and 5FU alone resulted in a >50% reduction in cell viability but CPL and DOX had no such effects. Only a combination of BCNU and PDF led to a drastic (~90%) cell viability reduction, accompanied by inactivation of Gly-I and an increase in oxidative stress. However, any combinations of other drugs and PDF had little effects on cell viability, Gly-I activity, or severity of oxidative stress.Conclusions: This study shows that anticancer activity of BCNU is significantly potentiated with PDF in T24 cells. This is rather attributed to inactivated Gly-I and increased oxidative stress. Therefore, PDF appears to have a chemosensitizing effect capable of enhancing BCNU cytotoxicity, which may offer an alternative, improved therapeutic option for bladder cancer.
- 26 August 2020
- Published by Medip Academy in International Journal of Research in Medical Sciences
- Vol. 8 (9) , 3154
Chemosensitizing effect of maitake mushroom extract on carmustine cytotoxicity in human bladder cancer cells
Background: Despite several therapeutic options available for bladder cancer, the outcomes are less satisfactory. To find a more effective modality, we were interested in the bioactive mushroom extract, PDF, which has been shown to sensitize certain anticancer drugs. Accordingly, we investigated if cytotoxic effects of several anticancer drugs used on bladder cancer patients could be enhanced with PDF in vitro.Methods: Human bladder cancer T24 cells were treated with four anticancer drugs, carmustine (BCNU), 5-fluorouracil (5FU), cisplatin (CPL), and doxorubicin (DOX) alone, their combinations, or in combination with PDF, and cell viability was determined. To explore the anticancer mechanism, the status of glyoxalase I (Gly-I), an enzyme involved in the drug resistance of cancer cells, and oxidative stress that can cause severe cellular injury/damage was also assessed.Results: BCNU and 5FU alone resulted in a >50% reduction in cell viability but CPL and DOX had no such effects. Only a combination of BCNU and PDF led to a drastic (~90%) cell viability reduction, accompanied by inactivation of Gly-I and an increase in oxidative stress. However, any combinations of other drugs and PDF had little effects on cell viability, Gly-I activity, or severity of oxidative stress.Conclusions: This study shows that anticancer activity of BCNU is significantly potentiated with PDF in T24 cells. This is rather attributed to inactivated Gly-I and increased oxidative stress. Therefore, PDF appears to have a chemosensitizing effect capable of enhancing BCNU cytotoxicity, which may offer an alternative, improved therapeutic option for bladder cancer.
- Open Access
- 1 October 2019
- Published by International Scientific Invention Journals in International Journal of Innovative Research in Medical Science
- Vol. 4 (10) , 600 to 606
Possible Prophylactic Effect of Poria Mushroom Extract on Chemically-Induced Chronic Kidney Disease In Vitro and In Vivo
Background: Hypothesizing that oxidative stress (OXS) could be a key pathogenic factor for the incidence of chronic kidney disease (CKD), we investigated if the Poria mushroom extract, PE, with possible antioxidant activity, would prevent the incidence of CKD in rats. Materials and Methods: Antioxidant activity of PE was examined against OXS induced by hydrogen peroxide (H2O2) in renal LLC-PK1 cells. Whether PE could prevent the development of CKD in the rat kidneys, mediated through adenine (ADN)-induced OXS, was also examined. After 2 weeks, blood and kidney specimens were collected from rats for blood, histopathologic, and biochemical analyses. Results: Although H2O2-induced OXS led to a significant cell viability reduction in LLC-PK1 cells, PE significantly diminished OXS and sustained high (~70%) cell viability. In rats, ADN-given rats showed typical renal dysfunction with palpable kidney damage; however, PE supplement improved renal function with better histology. A ~2.2-fold increased OXS level was also seen in ADN-given rats but it was reduced by ~27% with PE supplement. Moreover, analysis of kidney injury biomarkers further confirmed extended kidney damage by ADN. Nevertheless, PE effectively maintained the natural status of those markers, protecting the rat kidneys. Conclusions: OXS is indeed harmful to renal cells in vitro and could even lead to ADN-induced CKD in vivo. However, PE appears to have antioxidant activity capable of protecting renal cells and the rat kidneys from such detrimental OXS. Therefore, it is rather possible that PE could be a natural antioxidant with prophylactic effect against OXS-induced CKD.
- 1 October 2019
- Published by International Scientific Invention Journals in International Journal of Innovative Research in Medical Science
- Vol. 4 (10) , 600 to 606
Open AccessPossible Prophylactic Effect of Poria Mushroom Extract on Chemically-Induced Chronic Kidney Disease In Vitro and In Vivo
Background: Hypothesizing that oxidative stress (OXS) could be a key pathogenic factor for the incidence of chronic kidney disease (CKD), we investigated if the Poria mushroom extract, PE, with possible antioxidant activity, would prevent the incidence of CKD in rats. Materials and Methods: Antioxidant activity of PE was examined against OXS induced by hydrogen peroxide (H2O2) in renal LLC-PK1 cells. Whether PE could prevent the development of CKD in the rat kidneys, mediated through adenine (ADN)-induced OXS, was also examined. After 2 weeks, blood and kidney specimens were collected from rats for blood, histopathologic, and biochemical analyses. Results: Although H2O2-induced OXS led to a significant cell viability reduction in LLC-PK1 cells, PE significantly diminished OXS and sustained high (~70%) cell viability. In rats, ADN-given rats showed typical renal dysfunction with palpable kidney damage; however, PE supplement improved renal function with better histology. A ~2.2-fold increased OXS level was also seen in ADN-given rats but it was reduced by ~27% with PE supplement. Moreover, analysis of kidney injury biomarkers further confirmed extended kidney damage by ADN. Nevertheless, PE effectively maintained the natural status of those markers, protecting the rat kidneys. Conclusions: OXS is indeed harmful to renal cells in vitro and could even lead to ADN-induced CKD in vivo. However, PE appears to have antioxidant activity capable of protecting renal cells and the rat kidneys from such detrimental OXS. Therefore, it is rather possible that PE could be a natural antioxidant with prophylactic effect against OXS-induced CKD.
- 31 October 2018
- Published by Springer Nature in International Urology and Nephrology
- Vol. 51 (1) , 85-92
Prophylactic effect of ethyl pyruvate on renal ischemia/reperfusion injury mediated through oxidative stress
As oxidative stress (OXS) has been shown to play a primary role in renal ischemia/reperfusion injury (RIRI), we investigated whether antioxidant such as ethyl pyruvate (EPy) might effectively prevent RIRI. Possible prophylactic effects of EPy and mannitol (Mann), one of perioperative agents often used, were tested against harmful OXS in vitro.
- 31 October 2018
- Published by Springer Nature in International Urology and Nephrology
- Vol. 51 (1) , 85-92
Prophylactic effect of ethyl pyruvate on renal ischemia/reperfusion injury mediated through oxidative stress
As oxidative stress (OXS) has been shown to play a primary role in renal ischemia/reperfusion injury (RIRI), we investigated whether antioxidant such as ethyl pyruvate (EPy) might effectively prevent RIRI. Possible prophylactic effects of EPy and mannitol (Mann), one of perioperative agents often used, were tested against harmful OXS in vitro.
- 1 October 2017
- Published by SAGE Publications in Journal of Endourology
- Vol. 31 (10) , 1007-1011
Device-Related Adverse Events During Percutaneous Nephrolithotomy: Review of the Manufacturer and User Facility Device Experience Database
Introduction and Objectives: Percutaneous nephrolithotomy (PCNL) is an established technique for removal of large stones from the upper urinary tract. It is a complex multistep procedure requiring several classes of instruments that are subject to operator misuse and device malfunction. We report device-related adverse events during PCNL from the Manufacturer and User Facility Device Experience (MAUDE) database using a recently developed standardized classification system. Materials and Methods: The MAUDE database was queried for “percutaneous nephrolithotomy” from 2006 to 2016. The circumstances and patient complications associated with classes of devices used during PCNL were identified. We then utilized a novel MAUDE classification system to categorize clinical events. Logistic regression analysis was performed to identify associations between device classes and severe adverse events. Results: A total of 218 device-related events were reported. The most common classes included: lithotripter 53 (24.3%), wires 43 (19.7%), balloon dilators 30 (13.8%), and occlusion balloons 28 (12.8%). Reported patient complications included need for a second procedure 12 (28.6%), bleeding 8 (19.0%), retained fragments 7 (16.7%), prolonged procedure 4 (9.5%), ureteral injury 2 (4.8%), and conversion to an open procedure 3 (7.1%). Using a MAUDE classification system, 176 complications (81%) were Level I (mild/none), 26 (12%) were Level II (moderate), 15 (7%) were Level III (severe), and 1 (0.5%) was Level IV (life threatening). On univariate analysis, balloon dilators had the highest risk of Level II–IV complications compared with the other device classes [odds ratio: 4.33, confidence interval: 1.978, 9.493, p < 0.001]. The device was evaluated by the manufacturer in 93 (42.7%) cases, with 54.8% of reviewed cases listing the source of malfunction as misuse by the operator. Conclusions: PCNL is subject to a wide range of device-related adverse events. A MAUDE classification system is useful for standardized, clinically-relevant reporting of events. Our findings highlight the importance of proper surgeon training with devices to maximize efficiency and decrease harm.
- 1 October 2017
- Published by SAGE Publications in Journal of Endourology
- Vol. 31 (10) , 1007-1011
Device-Related Adverse Events During Percutaneous Nephrolithotomy: Review of the Manufacturer and User Facility Device Experience Database
Introduction and Objectives: Percutaneous nephrolithotomy (PCNL) is an established technique for removal of large stones from the upper urinary tract. It is a complex multistep procedure requiring several classes of instruments that are subject to operator misuse and device malfunction. We report device-related adverse events during PCNL from the Manufacturer and User Facility Device Experience (MAUDE) database using a recently developed standardized classification system. Materials and Methods: The MAUDE database was queried for “percutaneous nephrolithotomy” from 2006 to 2016. The circumstances and patient complications associated with classes of devices used during PCNL were identified. We then utilized a novel MAUDE classification system to categorize clinical events. Logistic regression analysis was performed to identify associations between device classes and severe adverse events. Results: A total of 218 device-related events were reported. The most common classes included: lithotripter 53 (24.3%), wires 43 (19.7%), balloon dilators 30 (13.8%), and occlusion balloons 28 (12.8%). Reported patient complications included need for a second procedure 12 (28.6%), bleeding 8 (19.0%), retained fragments 7 (16.7%), prolonged procedure 4 (9.5%), ureteral injury 2 (4.8%), and conversion to an open procedure 3 (7.1%). Using a MAUDE classification system, 176 complications (81%) were Level I (mild/none), 26 (12%) were Level II (moderate), 15 (7%) were Level III (severe), and 1 (0.5%) was Level IV (life threatening). On univariate analysis, balloon dilators had the highest risk of Level II–IV complications compared with the other device classes [odds ratio: 4.33, confidence interval: 1.978, 9.493, p < 0.001]. The device was evaluated by the manufacturer in 93 (42.7%) cases, with 54.8% of reviewed cases listing the source of malfunction as misuse by the operator. Conclusions: PCNL is subject to a wide range of device-related adverse events. A MAUDE classification system is useful for standardized, clinically-relevant reporting of events. Our findings highlight the importance of proper surgeon training with devices to maximize efficiency and decrease harm.
- 1 April 2017
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 197 (4) , e580-e581
PD30-08 DEVICE-RELATED DEVIATION DURING PERCUTANEOUS NEPHROLITHOTOMY: REVIEW OF THE MANUFACTURER AND USER FACILITY DEVICE EXPERIENCE (MAUDE) DATABASE
- 1 April 2017
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 197 (4) , e580-e581
PD30-08 DEVICE-RELATED DEVIATION DURING PERCUTANEOUS NEPHROLITHOTOMY: REVIEW OF THE MANUFACTURER AND USER FACILITY DEVICE EXPERIENCE (MAUDE) DATABASE
- 1 April 2016
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 195 (4S)
MP88-06 ANTICANCER AND CHEMOSENSITIZING EFFECTS OF 2-DEOXYGLUCOSE TARGETING GLYCOLYSIS IN HUMAN BLADDER CANCER CELLS
- 1 April 2016
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 195 (4S)
MP88-06 ANTICANCER AND CHEMOSENSITIZING EFFECTS OF 2-DEOXYGLUCOSE TARGETING GLYCOLYSIS IN HUMAN BLADDER CANCER CELLS